Marc de Garidel, Chief Executive Officer and Director at Abivax S.A.. Biography, career history and compensation sourced from SEC proxy filings.
About
Marc de Garidel has served as Abivax's Chief Executive Officer since May 5, 2023 and served as Interim Chairman of the Board from May 2023 to July 2024. He has more than 40 years of experience in the pharmaceutical and biotechnology sector, including 12 years as a biotech and pharmaceutical CEO. Between July 2021 and April 2023 he was Chief Executive Officer of CinCor Pharma, leading its sale for up to $1.8 billion to AstraZeneca in February 2023; from September 2020 to May 2021 he was CEO of AZTherapies; and from April 2018 to August 2020 he was CEO of Corvidia Therapeutics, which he led to a $2.1 billion sale to Novo Nordisk. He was Chief Executive Officer of Ipsen from November 2010 to July 2016 and earlier held roles of increasing responsibility at Amgen and Eli Lilly. He has chaired the board of Ipsen since 2010 and has been a director of Claris Bio since 2020. He holds a degree in Civil Engineering from the Ecole des Travaux Publics in Paris, a Master's degree in International Management from Thunderbird School of Global Management, and an executive MBA from Harvard Business School.
Roles
Abivax S.A.
Chief Executive Officer and Director · Current role
May 2023–present
Abivax
Chief Executive Officer (and Interim Chairman May 2023-July 2024)
2023 - present
CinCor Pharma
Chief Executive Officer · Led sale to AstraZeneca for up to $1.8 billion (Feb 2023)
2021 - 2023
AZTherapies
Chief Executive Officer
2020 - 2021
Corvidia Therapeutics
Chief Executive Officer · Led $2.1 billion sale to Novo Nordisk
2018 - 2020
Ipsen
Chief Executive Officer
2010 - 2016
Amgen / Eli Lilly
Roles of increasing responsibility
—
External Roles
Ipsen
Chairman of the Board
2010 - present
Claris Bio
Director
2020 - present
Fixed Compensation
FY 2025
Fixed compensation
€600,600
ComponentBase (fixed) remuneration earned in FY2025, reported in euros
Aggregate disclosureIndividual compensation is not broken out for this officer in the FY2025 20-F. Aggregate compensation paid and benefits in kind (including share-based compensation and vestings) to all current executive officers and directors was €24.8 million for the year ended December 31, 2025 (€19.1 million for 2024).
Performance Compensation
Data from FY 2025
Cash incentive
Variable annual compensation
€300,300
Target Opportunity
—
PlanAnnual variable remuneration (amount due for the prior year); granted under an equity plan in 2025
Exceptional variable compensation
€150,150
Target Opportunity
—
PlanExceptional variable remuneration awarded in FY2025
Stock awards
Free-share (AGA) awards granted in 2025
1,083,052 shares
FormAttributions gratuites d'actions (AGA): Free Shares 2025-1 (936,000), 2025-2 (47,052) and 2025-7 (100,000); no EUR grant-date fair value disclosed in the CEO compensation table; minimum 2-year acquisition period